Board of Directors
According to the articles of association, the board shall consist of not less than three and not more than nine directors, with no deputies.
The company meets the requirements in the Code, that a majority of the directors must be independent of the company and its senior management and that two within that majority must be independent of major shareholders in the company.
At the General Meeting 2025 it was resolved that the number of directors shall be five.
Anders Hallberg
Anders Hallberg
Chairman
Board memeber and chairman of the board since 2026.
Born 1973. Master’s degree in Economics and Bachelor’s degree in Business Administration from Lund University.
Other appointments: Chairman of the Board of Medivir AB and board member of Hallberg Management AB.
Previous assignments: Founder of HealthInvest Partners AB. Analyst and portfolio manager in the healthcare sector at Carnegie Investment Bank AB/Carnegie Asset Management AB.
Independent in relation to the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in KDventures 92,800,000 shares.
Board memeber and chairman of the board since 2026.
Born 1973. Master’s degree in Economics and Bachelor’s degree in Business Administration from Lund University.
Other appointments: Chairman of the Board of Medivir AB and board member of Hallberg Management AB.
Previous assignments: Founder of HealthInvest Partners AB. Analyst and portfolio manager in the healthcare sector at Carnegie Investment Bank AB/Carnegie Asset Management AB.
Independent in relation to the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in KDventures 92,800,000 shares.
Anna Lefevre Skjöldebrand
Anna Lefevre Skjöldebrand
Board member
Board members since 2021.
Born 1969. Master of Laws from Uppsala University.
Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (chairwoman) and Swecare and COCIR.
Previous assignments include: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Prevoius board assignments include i.a.: Dedicare AB, Danderyds Sjukhus AB, Södertälje Sjukhus Aktiebolag, Södersjukhuset Aktiebolag, E-hälsomyndigheten, SIS AB, Medtech Europe and St Eriks ögonsjukhus. She has also been a member of the board in the Board for Public Procurement.
Independent of the company, its executive management and independent in relation to the company’s major shareholders.
No holdings in KDventures.
Board members since 2021.
Born 1969. Master of Laws from Uppsala University.
Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (chairwoman) and Swecare and COCIR.
Previous assignments include: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Prevoius board assignments include i.a.: Dedicare AB, Danderyds Sjukhus AB, Södertälje Sjukhus Aktiebolag, Södersjukhuset Aktiebolag, E-hälsomyndigheten, SIS AB, Medtech Europe and St Eriks ögonsjukhus. She has also been a member of the board in the Board for Public Procurement.
Independent of the company, its executive management and independent in relation to the company’s major shareholders.
No holdings in KDventures.
Ben Toogood
Ben Toogood
Board member
Board members since 2021. Chairman since 2024.
Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.
Other appointments: CEO invoX Pharma Limited and Independent Board Member Jamjoom Pharma.
Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in KDventures: 64,001 shares.
Board members since 2021. Chairman since 2024.
Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.
Other appointments: CEO invoX Pharma Limited and Independent Board Member Jamjoom Pharma.
Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in KDventures: 64,001 shares.
Anders Bladh
Anders Bladh
Board member
Boardmember since 2026.
Born 1958. Master’s degree in International Business Administration from the University of Uppsala.
Other appointments: Chairman of the Board of Intervalor AB, Rimturs AB and Ribbskottet AB and board member of Xspray Pharma AB and Umecrine Cognition AB.
Previous assignments: Senior Vice President of Handelsbanken International and Corporate Finance departments, CEO of two real estate companies based in Holland and board member of Erik Penser Funds, Medirox AB and Distit AB. Founder and CEO of Intervalor AB.
Independent in relation to the company, its executive management and to the company’s major shareholders.
Holdings in KDventures 3,000,000 shares.
Boardmember since 2026.
Born 1958. Master’s degree in International Business Administration from the University of Uppsala.
Other appointments: Chairman of the Board of Intervalor AB, Rimturs AB and Ribbskottet AB and board member of Xspray Pharma AB and Umecrine Cognition AB.
Previous assignments: Senior Vice President of Handelsbanken International and Corporate Finance departments, CEO of two real estate companies based in Holland and board member of Erik Penser Funds, Medirox AB and Distit AB. Founder and CEO of Intervalor AB.
Independent in relation to the company, its executive management and to the company’s major shareholders.
Holdings in KDventures 3,000,000 shares.
Angelica Loskog
Angelica Loskog
Board member
Boardmember since 2026.
Born 1973. PhD in Clinical Immunology from Uppsala University.
Other appointments: CEO and board member of Lokon Pharma AB, scientific advisor to the investment company Nexttobe AB, Chairman of the Board of Repos Pharma AB and board member of Medivir AB.
Previous assignments: Chairman of the Board of Vivolux AB and Board member in Chemilia AB, Bioimics AB and Hansa Biopharma AB.
Independent in relation to the company, its executive management and to the company’s major shareholders.
No holdings in KDventures.
Boardmember since 2026.
Born 1973. PhD in Clinical Immunology from Uppsala University.
Other appointments: CEO and board member of Lokon Pharma AB, scientific advisor to the investment company Nexttobe AB, Chairman of the Board of Repos Pharma AB and board member of Medivir AB.
Previous assignments: Chairman of the Board of Vivolux AB and Board member in Chemilia AB, Bioimics AB and Hansa Biopharma AB.
Independent in relation to the company, its executive management and to the company’s major shareholders.
No holdings in KDventures.
